Pharmacogenetics in Cardiovascular Antithrombotic Therapy
- 15 September 2009
- journal article
- review article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 54 (12), 1041-1057
- https://doi.org/10.1016/j.jacc.2009.04.084
Abstract
No abstract availableThis publication has 114 references indexed in Scilit:
- Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort studyThe Lancet, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelThe New England Journal of Medicine, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsThe New England Journal of Medicine, 2009
- Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary interventionEuropean Heart Journal, 2008
- Assessment of coronary heart disease risk by combined analysis of coagulation factorsAtherosclerosis, 2008
- Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinClinical Pharmacology & Therapeutics, 2008
- Pharmacogenetics of warfarin: regulatory, scientific, and clinical issuesJournal of Thrombosis and Thrombolysis, 2007
- Impact of P-glycoprotein on clopidogrel absorptionClinical Pharmacology & Therapeutics, 2006
- Validation of Methods for CYP2C9 Genotyping: Frequencies of Mutant Alleles in a Swedish PopulationBiochemical and Biophysical Research Communications, 1999
- Effect of Intravenous Streptokinase on Left Ventricular Function and Early Survival after Acute Myocardial InfarctionThe New England Journal of Medicine, 1987